MALARIA

Selected abstract:

1.                  Girard MP, Reed ZH, Friede M, Kieny MP.  A review of human vaccine research and development: malaria. Vaccine. 2007 Feb 19;25(9):1567-80.

            University Paris 7, 39 rue Seignemartin, FR-69008 Lyon, France. marc.girard36@wanadoo.fr

            The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria infection and disease was demonstrated in African children. Pursued by various groups and on many fronts, several other candidate vaccines are in early clinical trials. Yet, despite the optimism and promise, an effective malaria vaccine is not yet available, in part because of the lack of understanding of the types of immune responses needed for protection, added to the difficulty of identifying, selecting and producing the appropriate protective antigens from a parasite with a genome of well over five thousand genes and to the frequent need to enhance the immunogenicity of purified antigens through the use of novel adjuvants or delivery systems. Insufficient clinical trial capacity and normative research functions such as local ethical committee reviews also contribute to slow down the development process. This article attempts to summarize the state of the art of malaria vaccine development.

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:

15880.  Doderer C, Heschung A, Guntz P, Cazenave JP, Hansmann Y, Senegas A, Pfaff AW, Abdelrahman T, Candolfi E.  A new ELISA kit which uses a combination of Plasmodium falciparum extract and recombinant Plasmodium vivax antigens as an alternative to IFAT for detection of malaria antibodies. Malar J. 2007 Feb 21;6:19. 

15881.  Fagbenro-Beyioku AF, Ojuromi OT, Orenaike IK.  Qualitative comparison of qualitative buffy coat and light microscopy in malaria diagnosis. Trop Doct. 2007 Jan;37(1):60-1.

15882.  Mueller I, Betuela I, Ginny M, Reeder JC, Genton B.  The sensitivity of the OptiMAL rapid diagnostic test to the presence of Plasmodium falciparum gametocytes compromises its ability to monitor treatment outcomes in an area of Papua New Guinea in which malaria is endemic. J Clin Microbiol. 2007 Feb;45(2):627-30.

15883.  Nosten F, McGready R, Mutabingwa T.  Case management of malaria in pregnancy. Lancet Infect Dis. 2007 Feb;7(2):118-25. Review. 

15884.  Talisuna AO, Meya DN.  Diagnosis and treatment of malaria. BMJ. 2007 Feb 24;334(7590):375-6. 

15885.  Venkatesh V, Patibandla PK, Agarwal GG, Awasthi S, Ahuja RC, Nag VL, Kushwaha KP, Agarwal SK.  Performance characteristics of a rapid diagnostic test for malaria, when used to confirm cerebral malaria in children and young adults. Ann Trop Med Parasitol. 2007 Jan;101(1):85-7.

15886.  Waltz E.  Practical malaria tests promise results in remote regions. Nat Med. 2007 Jan;13(1):6.

Vaccines:

15887.  Brown H.  New optimism over malaria vaccine research. Lancet Infect Dis. 2007 Feb;7(2):84.

15888.  Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ.  Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog. 2007 Feb;3(2):e25. 

15889.  Imoukhuede EB, Andrews L, Milligan P, Berthoud T, Bojang K, Nwakanma D, Ismaili J, Buckee C, Njie F, Keita S, Sowe M, Lang T, Gilbert SC, Greenwood BM, Hill AV.   Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. Am J Trop Med Hyg. 2007 Mar;76(3):486-93. 

15890.  Yadava A, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF.  A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun. 2007 Mar;75(3):1177-85. 

Chemotherapy, Immunotherapy, Management & Drugs: 

15891.  Andrews KT, Gatton ML, Skinner-Adams TS, McCarthy JS, Gardiner DL.  HIV-malaria interactions: don't forget the drugs. Science. 2007 Mar 30;315(5820):1791; author reply 1791.

15892.  Baldwin SA, McConkey GA, Cass CE, Young JD.  Nucleoside transport as a potential target for chemotherapy in malaria. Curr Pharm Des. 2007;13(6):569-80. Review. 

15893.  Greenwood B, Alonso P, ter Kuile FO, Hill J, Steketee RW. Malaria in pregnancy: priorities for research. Lancet Infect Dis. 2007 Feb;7(2):169-74. Review. 

15894.  Hunter A, Denman-Vitale S, Garzon L, Allen PJ, Schumann L. Global infections: recognition, management, and prevention. Nurse Pract. 2007 Feb;32(2):34-41; quiz 41-2. Review.

15895.  Kumar S, Guha M, Choubey V, Maity P, Bandyopadhyay U. Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update. Life Sci. 2007 Feb 6;80(9):813-28.

15896.  Linares GE, Rodriguez JB.  Current status and progresses made in malaria chemotherapy. Curr Med Chem. 2007;14(3):289-314. Review.  

15897.  Mufunda J, Nyarango P, Usman A, Gebremeskel T, Mebrahtu G, Ogbamariam A, Kosia A, Ghebrat Y, Gebresillosie S, Goitom S, Araya E, Andemichael G, Gebremichael A.    Roll back malaria--an African success story in Eritrea. S Afr Med J. 2007 Jan;97(1):46-50. 

15898.  Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C, Whitty CJ.   Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial. BMJ. 2007 Feb 24;334(7590):403.

15899.  Swales CA, Chiodini PL, Bannister BA; Health Protection Agency Advisory Committee on Malaria Prevention in UK Travellers.  New guidelines on malaria prevention: A summary. J Infect. 2007 Feb;54(2):107-10. 

15900.  Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW.    Paediatric malaria case-management with artemether-lumefantrine in Zambia: a  repeat cross-sectional study. Malar J. 2007 Mar 16;6:31.